Keryx Biopharmaceuticals Investor Alert: Investigation
An investigation for investors in Keryx Biopharmaceuticals shares over potential securities laws violations was announced and NASDAQ-KERX stockholders should contact the Shareholders Foundation at email@example.com
If you purchased shares of Keryx Biopharmaceuticals , you have certain options and you should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Keryx Biopharmaceuticals concerning whether a series of statements by Keryx Biopharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Shares of Keryx Biopharmaceuticals grew from as low as $0.124 per share in March 2009 to as high as $5.69 per share in May 2010.
On April 2, 2012, before the market opened, Keryx Biopharmaceuticals, Inc. reported that the Phase 3 "X-PECT" clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
Shares of Keryx Biopharmaceuticals dropped from $4.98 per share on Friday, March 30, 2012, to $1.74 per share on Monday, April 2, 2012 and continued to decline to as low as $1.28 per share on April 18, 2012.
On November 2, 2012, NASDAQ-KERX shares closed at $2.36 per share, less than half its current 52 week High.
Those who purchased shares of Keryx Biopharmaceuticals and currently hold those Keryx Biopharmaceuticals shares, may have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.